- Home
- INO vs ASPS Comparison
INO vs ASPS Comparison
Compare INO & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | ASPS |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 81.5M |
| IPO Year | 1999 | 2025 |
Fundamental Metrics
Financial Performance| Metric | INO | ASPS |
|---|---|---|
| Price | $0.73 | $5.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 4.0M | 26.4K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.18 | ★ 112.00 |
| EPS | N/A | ★ N/A |
| Revenue | $42,220,086.00 | ★ $942,213,000.00 |
| Revenue This Year | $20,156.19 | $9.17 |
| Revenue Next Year | $421.95 | $24.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $0.56 | $4.30 |
| 52 Week High | $2.86 | $14.36 |
Technical Indicators
Market Signals| Indicator | INO | ASPS |
|---|---|---|
| Relative Strength Index (RSI) | 33.01 | 40.92 |
| Support Level | $0.56 | $5.00 |
| Resistance Level | $1.24 | $6.15 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 31.29 | 33.03 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.